Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis

Second cancer in Philadelphia negative myeloproliferative neoplasms (MPN-K). A nested case-control study

(2019) Tiziano Barbui et al.   LEUKEMIA

Epidemiology, outcome, and risk factors for infectious complications in myelofibrosis patients receiving ruxolitinib: A multicenter study on 446 patients

(2018) Nicola Polverelli et al.   HEMATOLOGICAL ONCOLOGY

Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet

(2018) Tiziano Barbui et al.   LEUKEMIA

Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib

(2018) Massimo Breccia et al.   ANNALS OF HEMATOLOGY

Durability of spleen response affects the outcome of ruxolitinib-treated patients with myelofibrosis: Results from a multicentre study on 284 patients

(2018) Francesca Palandri et al.   LEUKEMIA RESEARCH

SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor–Naïve Patients With Myelofibrosis

(2017) Ruben A. Mesa et al.   JOURNAL OF CLINICAL ONCOLOGY

Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial

(2017) Srdan Verstovsek et al.   Journal of Hematology & Oncology

Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses

(2017) Srdan Verstovsek et al.   Journal of Hematology & Oncology

Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis

(2017) Francesca Palandri et al.   Oncotarget

Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study

(2017) Claire N Harrison et al.   Lancet Haematology

Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial

(2017) Ruben A Mesa et al.   Lancet Haematology

The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia

(2016) D. A. Arber et al.   BLOOD

Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: a snapshot of 1144 patients in the JUMP trial

(2016) H. K. Al-Ali et al.   HAEMATOLOGICA

Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis

(2016) C N Harrison et al.   LEUKEMIA

Impact of ruxolitinib treatment on the hemoglobin dynamics and the negative prognosis of anemia in patients with myelofibrosis

(2016) Haifa Kathrin Al-Ali et al.   LEUKEMIA & LYMPHOMA

Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: a snapshot of 1144 patients in the JUMP trial

(2016) H. K. Al-Ali et al.   HAEMATOLOGICA

The JAK-STAT Pathway: Impact on Human Disease and Therapeutic Intervention

(2015) John J. O'Shea et al.   Annual Review of Medicine

The effect of long-term ruxolitinib treatment on JAK2p.V617F allele burden in patients with myelofibrosis

(2015) M. Deininger et al.   BLOOD

Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group

(2015) N M Kröger et al.   LEUKEMIA

A Pilot Study of the Telomerase Inhibitor Imetelstat for Myelofibrosis

(2015) Ayalew Tefferi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ruxolitinib-associated tuberculosis: a case of successful ruxolitinib rechallenge

(2014) Francesca Palandri et al.   ANNALS OF HEMATOLOGY

Rationale for combination therapy in myelofibrosis

(2014) John Mascarenhas   BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY

Safety evaluation of ruxolitinib for treating myelofibrosis

(2014) Sofia Galli et al.   Expert Opinion On Drug Safety

Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report

(2013) A. Tefferi et al.   BLOOD

Ruxolitinib is a potent immunosuppressive compound: is it time for anti-infective prophylaxis?

(2013) A. Heine et al.   BLOOD

Myeloproliferative Neoplasm (MPN) Symptom Assessment Form Total Symptom Score: Prospective International Assessment of an Abbreviated Symptom Burden Scoring System Among Patients With MPNs

(2012) Robyn M. Emanuel et al.   JOURNAL OF CLINICAL ONCOLOGY

Dynamic International Prognostic Scoring System (DIPSS) predicts progression to acute myeloid leukemia in primary myelofibrosis

(2010) F. Passamonti et al.   BLOOD

PRM-151 (recombinant human serum amyloid P/pentraxin 2) for the treatment of fibrosis

(2010) J.S. Duffield et al.   DRUG NEWS & PERSPECTIVES

DIPSS Plus: A Refined Dynamic International Prognostic Scoring System for Primary Myelofibrosis That Incorporates Prognostic Information From Karyotype, Platelet Count, and Transfusion Status

(2010) Naseema Gangat et al.   JOURNAL OF CLINICAL ONCOLOGY